Consolidation, page-91

Good post SBarret, if I may build on it.....

I believe there are 165 000 aortic valve operations done annually in The US and perhaps the same in Europe bringing the total to 330 000..... I'd like to see AHZ capture 20% of these markets within 5 years.

If they can do that we'd see 66 000 aortic valve repair operations being done with CardioCel every year across The US and EU.

My understanding is that for these aortic valve repairs surgeons require (2) 5x8 CardioCel patches so that's 132 000 (5 x 8) CardioCel patches used annually withing 5 years if my thinking plays out.....

Why do I think it will?

i) Surgeons universally favor repair over replacement. What has stopped them up until now is that a suitable repair material has not been available. Professor Ozaki utilises autologous pericardium although this is both expensive and comes with a host of issues....

ii) Professor Ozaki has been intricately involved with AHZ's aortic venture to date.... This would suggest that he recognises the CardioCel ADAPT treated tissue as the best tissue to pair with his method for aortic valve repair and once more evidence has been garnered we should see an automatic coupling of Ozaki with Cardiocel, combining two best practice methods to create a new paradigm in aortic valve surgery. I wish them the best of luck as this has the potential to result in a much better quality of result/life for any patient which has to undergo this most demanding of cardiac surgical operations.

*I have only included The US and EU in the above example, obviously the world market is many times larger.